165 related articles for article (PubMed ID: 12639293)
61. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
62. Interferon-α2b gene-modified human bone marrow mesenchymal stem cells inhibit hepatocellular carcinoma by reducing the Notch1 levels.
Su Y; Cheng R; Zhang J; Qian J; Diao C; Ran J; Zhang H; Li L
Life Sci; 2015 Dec; 143():18-26. PubMed ID: 26518164
[TBL] [Abstract][Full Text] [Related]
63. Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder.
Inoue K; Chikazawa M; Fukata S; Yoshikawa C; Shuin T
Clin Cancer Res; 2002 Jul; 8(7):2389-98. PubMed ID: 12114444
[TBL] [Abstract][Full Text] [Related]
64. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
[TBL] [Abstract][Full Text] [Related]
65. Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.
Liu P; Zhang C; Chen J; Zhang R; Ren J; Huang Y; Zhu F; Li Z; Wu G
J Immunother; 2011 Apr; 34(3):320-6. PubMed ID: 21389866
[TBL] [Abstract][Full Text] [Related]
66. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
67. Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model.
Krepler C; Certa U; Wacheck V; Jansen B; Wolff K; Pehamberger H
J Invest Dermatol; 2004 Oct; 123(4):664-9. PubMed ID: 15373770
[TBL] [Abstract][Full Text] [Related]
68. Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.
Win-Piazza H; Schneeberger VE; Chen L; Pernazza D; Lawrence HR; Sebti SM; Lawrence NJ; Wu J
Cancer Lett; 2012 Jul; 320(1):81-5. PubMed ID: 22306001
[TBL] [Abstract][Full Text] [Related]
69. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo.
Vasvari GP; Dyckhoff G; Kashfi F; Lemke B; Lohr J; Helmke BM; Schirrmacher V; Plinkert PK; Beckhove P; Herold-Mende CC
Int J Cancer; 2007 Oct; 121(8):1697-704. PubMed ID: 17557286
[TBL] [Abstract][Full Text] [Related]
70. Antiangiogenic therapy and p53.
Hammond EM; Giaccia AJ
Science; 2002 Jul; 297(5581):471; discussion 471. PubMed ID: 12142499
[No Abstract] [Full Text] [Related]
71. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
[TBL] [Abstract][Full Text] [Related]
72. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects.
Yi T; Elson P; Mitsuhashi M; Jacobs B; Hollovary E; Budd GT; Spiro T; Triozzi P; Borden EC
Oncotarget; 2011 Dec; 2(12):1155-1164. PubMed ID: 22201704
[TBL] [Abstract][Full Text] [Related]
73. Superior Antitumor Efficacy of IFN-α2b-Incorporated Photo-Cross-Linked Hydrogels Combined with T Cell Transfer and Low-Dose Irradiation Against Gastric Cancer.
Liu Q; Zhang D; Qian H; Chu Y; Yang Y; Shao J; Xu Q; Liu B
Int J Nanomedicine; 2020; 15():3669-3680. PubMed ID: 32547021
[TBL] [Abstract][Full Text] [Related]
74. Differential resistance of melanoma cells to treatment with recombinant IFN-alpha2b and leukocyte IFN.
Ruuth K; Berglund A; Munoz V; Lundgren E
Anticancer Res; 2007; 27(4B):2109-14. PubMed ID: 17695493
[TBL] [Abstract][Full Text] [Related]
75. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide.
Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL
BJU Int; 2002 Apr; 89(6):591-5. PubMed ID: 11942970
[TBL] [Abstract][Full Text] [Related]
76. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits.
Verheul HM; Panigrahy D; Yuan J; D'Amato RJ
Br J Cancer; 1999 Jan; 79(1):114-8. PubMed ID: 10408702
[TBL] [Abstract][Full Text] [Related]
77. Antiproliferative properties of chemically modified recombinant IFN-alpha2b.
Martynov AV; Smelyanskaya MV
J Interferon Cytokine Res; 2005 Jul; 25(7):414-7. PubMed ID: 16022586
[TBL] [Abstract][Full Text] [Related]
78. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha.
Ozawa S; Shinohara H; Kanayama HO; Bruns CJ; Bucana CD; Ellis LM; Davis DW; Fidler IJ
Neoplasia; 2001; 3(2):154-64. PubMed ID: 11420751
[TBL] [Abstract][Full Text] [Related]
79. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms.
McCarty MF; Bielenberg D; Donawho C; Bucana CD; Fidler IJ
Clin Exp Metastasis; 2002; 19(7):609-15. PubMed ID: 12498390
[TBL] [Abstract][Full Text] [Related]
80. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.
Pribluda VS; Gubish ER; Lavallee TM; Treston A; Swartz GM; Green SJ
Cancer Metastasis Rev; 2000; 19(1-2):173-9. PubMed ID: 11191057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
